Citizens Downgrades Cellectis to Market Perform
Citizens analyst Silvan Turkcan downgrades Cellectis (NASDAQ:CLLS) from Market Outperform to Market Perform.
Share
Why It Matters
A big financial expert said Cellectis is no longer a standout company. Now it is just like most other companies, so watch for what changes next.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.